CLINICAL STUDY ON THE ANTI-HBV EFFECT OF L-HAS-Ara-AMP-A RECEPTOR TARGETED DRUG
Abstract：OBJECTIVE:To observe the clinical efficacy of L-HAS-Ara-AMP (lactoaminated human serum albumin arabinoside adenine monophosphate), a receptor targeted drug. METHODS: 56 patients with chronic hepatitis B were entered into the study. 29 of them were treated with L-HASAra-AMP in a daily dose of 35 mg/kg for 5 days or 28 days;the rest were used as control and treated with Ara-AMP in a daily dose of 10 mg/kg. RESULTS:In the 5 days group, there are 10 patients with positive HBeAg and 8 patients with positive HBV-DNA,after treatment 3 of the former and 4 of the later temporaryly turned into negative and reversed a month later. In the 28 days group, a HBeAg negative-turning rate of 31.65 % ,a HBeAg titer decresing rate of 47.4 %, and an effective rate of 79.0% were obtained after treatment, these parameters didn' t reversed even 3 months later. No adverse rections were observed. CONCLUSION:L-HAS-Ara-AMP is effective in treatment of HBV infections and its anti-viral activity even in very low doses is more powerful than that of free Ara-AMP with no obvious side effects.
Keywords：Targeting treatmentChronic hepatitis B
Publication Date：1999-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：3( 827-829 )